This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2024 Remove Animal Testing Remove Protein Expression Remove Research
article thumbnail

A therapy candidate for fatal prion diseases turns off disease-causing gene

Broad Institute

JUNE 27, 2024

By Greta Friar, Whitehead Institute June 27, 2024 Images of a mouse brain show the effect of a technology called CHARM in turning off the expression of a gene in the brain. Previous research has shown that as little as 21 percent elimination of the protein can improve symptoms. Credit: Neumann EN, Bertozzi TM, et al.

Disease 142
Disease Therapies Engineering Clinical Trials 142
article thumbnail

Rapid delivery of toxicological material

Drug Target Review

SEPTEMBER 10, 2024

This approach also requires an early identification of molecular liabilities and rheological properties, generally using research-grade material supply, in conjunction with in-silico modelling to de-risk drug formulation. FDA no longer has to require animal testing for new drugs. References: 1 Wadman M. 4 Berrie J, Donninger R.

Clinical Supply 64
Clinical Supply Drug Development Production Animal Testing 64
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 15,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024